A novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving high receptor occupancy

CC Chemokine Receptor 2 (CCR2) and its endogenous ligand CCL2 are involved in a number of diseases, including atherosclerosis. Several CCR2 antagonists have been developed as potential therapeutic agents, however their in vivo clinical efficacy was limited. In this report, we aimed to determine whet...

Descripción completa

Detalles Bibliográficos
Autores principales: Bot, Ilze, Ortiz Zacarías, Natalia V., de Witte, Wilhelmus E. A., de Vries, Henk, van Santbrink, Peter J., van der Velden, Daniël, Kröner, Mara J., van der Berg, Dirk-Jan, Stamos, Dean, de Lange, Elizabeth C. M., Kuiper, Johan, IJzerman, Adriaan P., Heitman, Laura H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427923/
https://www.ncbi.nlm.nih.gov/pubmed/28246398
http://dx.doi.org/10.1038/s41598-017-00104-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427923/
https://www.ncbi.nlm.nih.gov/pubmed/28246398
http://dx.doi.org/10.1038/s41598-017-00104-z

Ejemplares similares